Literature DB >> 10722449

Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission.

B Christensson1, T Wiebe, A Akesson, A Widell.   

Abstract

Twenty-eight cases of hepatitis C virus (HCV) infection were identified in children in a pediatric oncology ward during 2 nosocomial outbreaks. HCV infection spontaneously cleared in 6 patients (21%). Eleven patients with persistent HCV viremia who had malignant diseases in remission after treatment were given a 48-week course of combined therapy with interferon-alpha (5x106 U 3 times weekly) and oral ribavirin (15 mg/kg/d). Seven (64%) of the 11 patients had sustained virological responses 6 and 12 months after cessation of therapy. Side effects were common but generally were mild or moderate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722449     DOI: 10.1086/313709

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.

Authors:  Magdalena Figlerowicz; Wojciech Sluzewski; Arleta Kowala-Piaskowska; Iwona Mozer-Lisewska
Journal:  Eur J Pediatr       Date:  2004-02-27       Impact factor: 3.183

Review 2.  A brief history of the treatment of viral hepatitis C.

Authors:  Doris B Strader; Leonard B Seeff
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-03-06

Review 3.  Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 5.  Pediatric issues in new therapies for hepatitis B and C.

Authors:  Kathleen B Schwarz
Journal:  Curr Gastroenterol Rep       Date:  2003-06

Review 6.  Hepatitis C virus infection in children coinfected with HIV: epidemiology and management.

Authors:  Massimo Resti; Chiara Azzari; Flavia Bortolotti
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  Treatment of hepatitis C in children: a systematic review.

Authors:  Jia Hu; Karen Doucette; Lisa Hartling; Lisa Tjosvold; Joan Robinson
Journal:  PLoS One       Date:  2010-07-13       Impact factor: 3.240

8.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

9.  Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study.

Authors:  Meagan Lansdale; Sharon Castellino; Neyssa Marina; Pamela Goodman; Melissa M Hudson; Ann C Mertens; Stephanie M Smith; Wendy Leisenring; Leslie L Robison; Kevin C Oeffinger
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

10.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.